In prostate cancer, generation of AR-V7 encoded by a splice variant of AR may confer resistance to androgen inhibitor treatment23, whereas few specific biomarkers predicting the efficacy of CAB treatment have been identified in SDC24–28. Here, AR is linked to prostate cancer.